Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).
This study is testing a new cell therapy called ALLO-501A, along with another drug called ALLO-647, for adults with a type of blood cancer called Large B-Cell Lymphoma, where previous treatments haven't worked. It aims to see how safe and effective these new treatments are.
For: Large B-Cell Lymphoma (LBCL)Italy · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy
This study is testing a new way to prepare people with a type of lymphoma (LBCL) for a special cell therapy called ALLO-501A. It compares two methods of preparing the body to see which works best and is safest.
For: Large B-Cell Lymphoma (LBCL)Belgium · Germany · Austria - Ongoing, recruitingTherapeutic exploratory (Phase II)
C5691004 _ A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression
This study is testing a new way to treat a type of cancer called peripheral T-cell lymphoma (PTCL). Researchers want to see if combining a newer drug (brentuximab vedotin) with standard chemotherapy (CHP) works well for people with a specific type of PTCL.
For: Peripheral T-cell LymphomaSpain · Italy · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
This study is looking at a new treatment called KTE-X19 for a type of cancer called Mantle Cell Lymphoma. It's for people whose cancer has come back or hasn't responded to previous treatments. Researchers want to see how well the new treatment shrinks the cancer.
For: Relapsed/Refractory Mantle Cell LymphomaFrance · Spain · Germany - AuthorisedTherapeutic exploratory (Phase II)
A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY TO DETERMINE THE SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PARTICIPANTS WITH SEVERE, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS WITH ACTIVE LUPUS NEPHRITIS
This study is looking at a new treatment called obe-cel for severe lupus that affects the kidneys. We want to see if it helps reduce kidney problems and improve overall health, and if it's safe for people aged 18 and over.
For: Systemic Lupus Erythematosus with Active Lupus NephritisGreece